Vascular Pathways of Los Altos, CA, says it has raised $14 million in a Series B round led by CHL Medical Partners. Ascension Health Ventures, MVM Life Science Partners, and Arcus Ventures also participated in the round. Vascular Pathways will use the money to commercialize its Rapid Intravascular Start (RIVS) IV catheter, which has been cleared by the FDA. The company says the catheter is an improvement on current peripheral intravenous catheters, which can be difficult and painful to insert. As part of the funding, Myles Greenberg of CHL, Walter Lin of Ascension Health, and Stephen Reeders of MVM have joined Vascular Pathways board.